Coronavirus Update: GSK Stresses Need For Broad Vaccines Amid Future Pandemic Risk
Also, Neoimmune looks to interleukin therapy for mild therapy while Daiichi Sankyo bets on a mRNA vaccine.
You may also be interested in...
The company finalized the Phase III program based on feedback from the US FDA and plans to start the study in July. With a 100 µg dose, Moderna says it can manufacture 500 million doses a year.
An official announcement is expected within weeks, as competition between US and China stokes fears of 'vaccine nationalism'.
C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.